Pfizer , Ibrance . FDA Expands Use of Breast Cancer Drug to Men .

The US Food and Drug Administration (FDA) has extended the indication of the breast cancer drug palbociclib (Ibrance, Pfizer) to include male patients.

Palbociclib capsules are used in combination with specific endocrine therapies for hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced or metastatic breast cancer.

The drug was initially approved in 2015. ...